All Resources

Patented Medicine Prices Review Board (PMPRB) • December 05, 2022

The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals

Learn more | View

Economic Impact • October 07, 2022

Pre-Budget Consultations in Advance of the 2023 Budget

Learn more | View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more | View

January 14, 2022

2022 Ontario Pre-Budget Consultation

Learn more | View

Ethics • January 01, 2022

2022 Code of Ethical Practices

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • August 31, 2021

PMPRB Notice and Comment Response

Learn more | View

Access to Medicine • August 06, 2021

2022 Federal Pre-Budget Consultation

Learn more | View

Private Drug Coverage • August 01, 2021

Cost Drivers: Analysis of Private Drug Plans in Canada 2021

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • June 21, 2021

Proposed Guidelines Monitoring and Evaluation Plan

Learn more | View

Vaccine Equity • April 30, 2021

Standing Committee on International Trade (CIIT) study of Canada’s International Trade and Investment Policy

…to support its study of Canada’s trade agreements and trade and investment policies regarding how they may help or hinder the production and distribution of COVID-19 vaccines domestically and abroad….

Learn more | View

Access to Medicine • March 31, 2021

Making Canada an International Life Sciences Leader

Learn more | View

Drugs for Rare Diseases (DRD) • March 26, 2021

Towards a Value-based and Pan-Canadian Rare Disease Strategy

Learn more | View